
Multiple Myeloma
Latest News
Advertisement
Latest Videos

Advertisement
More News

LUXEMBOURG-The bisphos-phonate pamidronate (Aredia) not only reduced skeletal morbidity but also relieved pain, reduced analgesic use, and improved quality of life in a multicenter study reported at the 7th International Symposium of the Multinational Association of Supportive Care in Cancer.

ROCKVILLE, Md--In a move with very little precedent, the FDA Oncologic Drugs Advisory Committee (ODAC) recommended approval of a new indication for the bisphosphonate Aredia (pam-idronate disodium for injection) on the basis of a single clinical trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Acid Reducers, Drug-Drug Interactions, and Setting Expectations for Response
2
Meaning-Centered Therapy, Psychiatry Referrals, and Humanistic Cancer Care
3
How Psycho-Oncology Addresses Existential Distress, Body Image, and Intimacy
4
How to Work With a Patient Who Declines Cancer Treatment
5

































































